Molecular classification of Crohn's disease reveals two clinically relevant subtypes by Weiser, Matthew et al.
Molecular classification of Crohn’s disease reveals two clinically 
relevant subtypes
Matthew Weiser*,1,2, Jeremy M. Simon*,1, Bharati Kochar2,3, Adelaide Tovar3,4, Jennifer W. 
Israel1, Adam Robinson3, Gregory R. Gipson3, Matthew S. Schaner3, Hans H. Herfarth3, R. 
Balfour Sartor3, Dermot P.B. McGovern5, Reza Rahbar6, Timothy S. Sadiq6, Mark J. 
Koruda6, Terrence S. Furey1,2,7,*, and Shehzad Z. Sheikh1,2,3,4,*
1Department of Genetics, University of North Carolina at Chapel Hill
2Curriculum in Bioinformatics and Computational Biology, University of North Carolina at Chapel 
Hill
3Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill
4Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill
5F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai 
Medical Center, Los Angeles, California
6Department of Surgery, University of North Carolina at Chapel Hill
7Department of Biology, University of North Carolina at Chapel Hill
Abstract
Objective—The clinical presentation and course of Crohn’s disease (CD) is highly variable. We 
sought to better understand the cellular and molecular mechanisms that guide this heterogeneity, 
and characterize the cellular processes associated with disease phenotypes.
Design—We examined both gene expression and gene regulation (chromatin accessibility) in 
non-inflamed colon tissue from a cohort of adult CD and control patients. To support the 
generality of our findings, we analyzed previously published expression data from a large cohort 
of treatment-naïve pediatric CD and control ileum.
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Results—We found that adult CD patients clearly segregated into two classes based on colon 
tissue gene expression—one that largely resembled the normal colon and one where certain genes 
showed expression patterns normally specific to the ileum. These classes were supported by 
changes in gene regulatory profiles observed at the level of chromatin accessibility, reflective of a 
fundamental shift in underlying molecular phenotypes. Further, gene expression from the ilea of 
the treatment-naïve pediatric CD patient cohort could be similarly subdivided into colon- and 
ileum-like classes. Finally, expression patterns within these CD subclasses highlight large-scale 
differences in the immune response and aspects of cellular metabolism, and were associated with 
multiple clinical phenotypes describing disease behavior, including rectal disease and need for 
colectomy.
Conclusion—Our results strongly suggest that these molecular signatures define two clinically 
relevant forms of CD irrespective of tissue sampling location, patient age or treatment status.
Keywords
Crohn’s disease; RNA expression; gene regulation; IBD clinical; IBD molecular subtypes
INTRODUCTION
Crohn’s disease (CD) is a chronic heterogeneous inflammatory disorder with distinct 
patterns of clinical behavior. CD may present or evolve with time into a more complex 
phenotype with patients developing strictures, fistulae, and/or abscesses, and many patients 
experience highly variable response to therapies. Genetic associations[1, 2] and a recently 
defined lipid metabolism-based gene expression signature predictive of disease 
involvement[3] suggest that molecular or genetic factors are associated with and may 
contribute to disease heterogeneity, but precise mechanisms are poorly understood. 
Molecular subtypes defined by gene expression that impact clinical phenotypes have also 
been documented in other complex diseases, especially cancers[4, 5, 6]. Whether adult CD 
can be similarly separated into two or more subgroups and whether these molecular classes 
can explain disease phenotypes remains largely unknown.
Understanding how genes are regulated provides complementary information to gene 
expression. We and others have studied gene regulation by focusing on accessible chromatin, 
which allows transcriptional regulators to bind to the otherwise highly condensed nuclear 
genome. Chromatin accessibility has been associated with promoters, enhancers, silencers, 
and insulators[7], and changes as cellular identity is established through differentiation and 
development[8, 9] or in response to cellular stresses. Chromatin profiling provides a 
mechanism as to why expression is changing, and whether observed changes may be 
transient or persistent. We have shown that chromatin accessibility can differentiate disease 
subtypes[10] and helps to describe genetic and environmental contributors to disease[11]. 
We therefore sought to determine whether multiple clinically distinct subclasses of adult CD 
exist by examining both gene expression, using RNA-seq, and chromatin accessibility, using 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE-seq)[12], in CD and non-
IBD patient samples of unaffected colon mucosa.
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RESULTS
Whole genome interrogation of the colonic transcriptional and chromatin landscape 
reveals two distinct molecular classes in Crohn’s disease
To determine, in an unbiased manner, whether gene expression levels separated samples into 
distinct molecular groups, we performed a principal components analysis (PCA) using gene 
expression profiles from a combined set of 21 CD and 11 non-IBD patients. A striking 
clustering pattern emerged whereby the CD individuals were divided into two distinct, 
expression-based subclasses, one of which clustered with the non-IBD controls (Figure 1A). 
To specifically interrogate these two CD subclasses, we identified genes differentially 
expressed between these two groups of CD patients (849 genes at FDR<0.05; Figure 1B, see 
Supplementary Table 1 for top 20 differentially expressed genes in each CD subclass). 
Surprisingly, when looking at the top 25 differentially expressed genes regardless of 
direction, most had tissue-specific expression patterns that discriminated colon from the 
small intestine (ileum), including NXPE4, CWH43, and CA2 (colon-specific), as well as 
RBP2, TM6SF2, APOB, MTTP, CREB3L3, and CPS1 (ileum-specific)[13]. CD samples 
similar to non-IBD controls (Figure 1A) exhibited abundant expression of the above colon-
specific genes, whereas the other CD subclass showed expression patterns more consistent 
with ileum despite being sampled from the colon. To explore this more globally, we 
compared all these differentially expressed genes to 947 genes with known significant 
differential expression between colon and ileum (Figure 1C)[14]. We found that 34% of the 
genes more highly expressed in the colon-like CD samples were indeed markers of normal 
colon, and 44% of ileum marker genes were more highly expressed in the ileum-like CD 
samples (p<1×10−95, hypergeometric test). To validate these expression differences, we 
performed RT-qPCR on 18 CD samples of unaffected colon mucosa (9 colon-like, 9 ileum-
like) using CEACAM7 and APOA1 as a proxy for colon-like and ileum-like expression 
patterns (Supplementary Figure 1A). In agreement with the RNA-seq data, CEACAM7 was 
significantly more abundant in colon-like CD samples (p=0.017, one-sided t-test), whereas 
APOA1 was significantly more abundant in ileum-like CD samples (p=0.020, one-sided t-
test).
To determine whether these expression changes represented a fundamental shift in the 
functional cellular identity of these tissues, we investigated chromatin accessibility by 
performing FAIRE-seq[12] on the same samples from both CD subclasses. Supporting a 
fundamental shift in underlying molecular phenotypes, we identified 3,339 300-bp regions 
with significantly differential chromatin accessibility between colon-like and ileum-like CD 
samples (Figure 1D; p<0.05, two-sided t-test), hereafter referred to as Differentially 
Accessible Regions (DARs). These DARs could be divided into two classes based on greater 
accessibility in colon-like or ileum-like CD samples, and further, an unsupervised PCA of 
FAIRE-seq data nearly separated ileum-like from colon-like CD subclasses (Supplementary 
Figure 1C). Subclass-specific changes in the chromatin landscape corresponded strongly to 
differences in nearby (within 50 kb) gene expression (Figure 1E–F; p≤0.01, permutation). 
Additionally, both colon-specific and ileum-specific DARs exhibited a significant 
enrichment for CD GWAS SNP loci[15] compared to what was expected due to random 
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chance (colon-specific p=0.018, ileum-specific p=0.006; permutation), suggestive that 
changes in chromatin accessibility occur at disease relevant regions of the genome.
We next sought to annotate these DARs based on tissue-specific gene regulatory 
information. Post-translational modifications on histone proteins serve to compartmentalize 
the genome and demarcate putative function of regulatory elements[16]. Using ChIP-seq 
data from the Roadmap Epigenomics Project[17], we assessed the enrichment of seven 
histone modifications reflective of underlying regulatory activity (active: H3K4me1, 
H3K4me3, H3K27ac, H3K36me3; repressive: H3K27me3, H3K9me3) around colon-
specific and ileum-specific DARs. We found that colon-specific DARs were demarcated by 
H3K27ac and H3K4me1 modifications present in colon but not ileum (Supplementary 
Figure 1B), suggesting these DARs function as active regulatory regions only in the normal 
colon. In contrast, ileum-specific DARs demonstrated positive H3K27ac and H3K4me1 
enrichment found only in normal small intestine, despite these samples originating from 
colon tissue. These suggest that regulatory activity in DARs contribute to the colon-like and 
ileum-like expression levels. To confirm regulatory activity, we cloned three DARs (two 
with colon-specific and one with ileum-specific chromatin accessibility) into luciferase 
vectors upstream of a minimal promoter in both orientations using THP-1 monocytes 
(Supplementary Figure 1D). Relative to empty vector controls, two DARs (associated with 
SATB2-AS1 and DEPDC7) exhibited a significant increase (p<0.01, one-sided t-test) in 
luciferase activity in both orientations, strongly suggestive of enhancer function. The third 
DAR (associated with SLC16A9) also enhanced luciferase activity significantly 
(p=8.9×10−5, one-sided t-test), however only in the reverse orientation.
Together, these data support the existence of two molecularly distinct subclasses of CD. 
Further, chromatin accessibility data suggests these subclasses exist due to stable molecular 
transformations of the genomic architecture in colon tissue cells, and not transient 
differences due to external cellular signaling.
Whole genome RNA-seq analysis reveals colon-like and ileum-like subclasses in 
treatment-naïve pediatric Crohn’s disease patients
Gene expression profiles in adult CD patients may vary due to patient treatment histories. 
Therefore, we sought to determine whether treatment-naïve pediatric CD patients also 
segregated into similar molecular classes. We performed PCA on previously published 
RNA-seq data from ileal biopsies in age-matched pediatric CD (n=201) and non-IBD (n=40) 
patients generated within the Pediatric Risk Stratification Study[3]. Though a clustering as 
distinct as with the adult samples was not observed, non-IBD ileum samples clustered with 
some CD samples along the first principal component, whereas the other CD samples were 
separate (Supplementary Figure 2). To determine whether this pattern was related to the 
adult CD molecular subtypes, we performed PCA on combined adult colon and pediatric 
ileum expression data (Figure 2A). Unsurprisingly, samples predominantly separated by 
tissue of origin (colon vs. ileum; first principal component). However, a separation indicative 
of two molecular subclasses was evident along the second principal component, and 
correlated nearly exactly with the first principal components in single cohort PCAs (Figure 
1A, Supplementary Figure 2). Further, pediatric CD samples fell on a spectrum highly 
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correlated with expression of APOA1, a marker gene of the ileum and indicator of disease 
outcome in the pediatric cohort[3]. This pattern aligned well with the ileum-like (APOA1-
high) and colon-like (APOA1-low) subclasses we identified in the adult CD colon.
To closely examine the relationship between the two CD subclasses across the adult and 
pediatric cohorts, we assessed gene expression patterns across the 500 most-variably-
expressed known colon and ileum marker genes[14] using hierarchical clustering (Figure 
2B). To focus this analysis, we selected the 50 pediatric ileum samples each that were most 
colon-like and most ileum-like based on the PCA (Figure 2A, second PC). Many of the 
colon and ileum representative genes described above (e.g. APOA1, CEACAM7, MTTP, 
LEFTY1, and CA2) exhibited highly consistent expression patterns across all samples in a 
defined molecular subclass, regardless of cohort. Interestingly, for these 500 genes, 
expression patterns were extremely consistent between colon-like CD and non-IBD colon 
samples, as well as between ileum-like CD and non-IBD ileum samples. Importantly, we 
note that a subset of genes differentiate all colon tissues from all ileum tissues indicating that 
tissue-of-origin-specific expression is not completely lost. Together, these data strongly 
suggest that the colon-like and ileum-like molecular signatures define two forms of CD 
present regardless of tissue sampling location, patient age, or treatment status.
Metabolic and immune activation gene expression profiles characterize distinct molecular 
phenotypes in adult and pediatric CD
Gene expression differences between colon-like and ileum-like subclasses in the adult and 
pediatric CD cohorts went beyond the marker genes described above (Figure 1B–C). To 
evaluate this more broadly, we computed and compared pathway-level expression patterns of 
both CD subclasses and non-IBD controls in both patient cohorts[18, 19]. We then grouped 
significantly altered pathways based on similarity in both gene composition and direction of 
expression difference (Figure 3, Supplementary Figures 3 and 4). First, numerous pathways 
related to interferon signaling, GPCR signaling, and antigen processing were significantly 
upregulated in CD patients as a whole relative to non-IBD controls in both cohorts 
(Supplementary Figure 3, “CD-enriched”, red). Given that the adult patient cohort consisted 
of disease-unaffected tissue, and the pediatric cohort was treatment-naïve, this suggests a 
basal activation of the immune system in CD. In contrast, many pathways related to the 
RNA processing, translation, and transcription were downregulated in CD in the pediatric 
patients (Supplementary Figure 3, “CD-depleted”, blue). These results strongly corroborate 
studies in mice and humans linking overall defects in cellular protein processing in CD to 
immune activation and unabated inflammation[20].
Next, we identified significantly altered pathways that described how the ileum-like and 
colon-like CD subclasses differed. Among the most pronounced effects in both cohorts 
reflected strong differences in metabolic activity including pathways involved in lipid 
metabolism and metabolism of foreign (xenobiotic) agents (Figure 3A; “Ileum-like-
enriched”, red; Figure 3B; “Colon-like-depleted”; blue). Interestingly, energy production by 
way of the TCA cycle was significantly affected in opposing ways: in adults, it was 
upregulated in the colon-like class and simultaneously downregulated in the ileum-like class 
in colon tissue (Figure 3A; “Colon-like-enriched, Ileum-like-depleted”, pink); whereas in 
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pediatric patients it was downregulated in the colon-like class and upregulated in the ileum-
like class in ileal tissue (Figure 3B; “Ileum-like-enriched, Colon-like-depleted”, purple). 
This suggests that energy production increases in patients where the subtype is more similar 
to the tissue of origin, and decreases when gene expression adopts patterns of the opposite 
tissue. In addition, several pathways related to G-protein coupled receptor (GPCR) signaling 
were upregulated in the ileum-like subclass in colon tissue (Figure 3A; “Ileum-like-
enriched”, red) and upregulated in the colon-like subclass in ileum tissue (Figure 3B; 
“Colon-like-enriched”, green). GPCRs are highly expressed in monocytes and macrophages 
central to the development and progression of inflammation in CD, mainly through 
migration and accumulation within the inflamed tissues[21].
Taken together, dysregulation of metabolic pathways may represent defining features of CD 
subtypes. Although dysregulation of lipid metabolism has been previously described in 
CD[3], our data suggest these alterations may be specific only to patients within a certain 
subclass and dependent on the tissue being assayed. Further, these data indicate that despite 
a striking similarity in expression of key ileum and colon marker genes (Figure 2B), there 
are key differences in pathway-level expression patterns between adult and pediatric CD 
patients, such as the immune response (e.g. NOD/TLR signaling, interleukin signaling), that 
point toward clinically relevant phenotypes and characteristics of each subclass.
Molecular subclasses are associated with clinical outcomes
To understand the impact of molecular phenotype on clinical disease, we studied the clinical 
characteristics of treatment-naïve pediatric patients with respect to molecular 
subclassification. We again used the 50 ileum-like and 50 colon-like pediatric samples 
defined above. We found that significantly more colon-like CD patients displayed both colon 
and ileum involvement (p=0.0014), had deep ulcers (p=0.0002), and showed macroscopic 
inflammation (p=0.0156), whereas more ileum-like patients showed no inflammation 
(p=0.0122) and a strong skew in prevalence towards colon-only involvement (p=0.0528; 
Table 1).
We next performed an in-depth retrospective chart review and a prospective follow-up of all 
adult CD patients (Table 1; Supplementary Table 1) to see if a similar clinical impact of 
molecular subclass was observed. Patients with colon-like CD had greater rectal disease 
involvement (p<0.01) and were more likely to eventually need a colectomy (p=0.01). 
Patients with ileum-like CD tended to have ileal disease (p=0.06) and required the use of 
post-operative biological therapy (p=0.02). Though our sample size is small, these data 
suggest that molecular subtypes of CD can stratify patients into clinically distinct and 
relevant subgroups, and may prospectively identify those more likely to require intensive 
medical therapy.
DISCUSSION
We identified two distinct molecular phenotypes in colon tissue obtained from adult CD 
patients. When we applied the same analytical approach to pediatric RNA-seq data from 
ileum, two molecular phenotypes also emerged, albeit the clinical consequences in both 
circumstances were relevant to the population of study and limited to the data collected for 
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each population in terms of clinical phenotype. Although the adult patient sample size was 
limited, in only the colon-like CD subclass were there patients with rectal disease, or that 
required a colectomy. Rectal CD is particularly difficult to manage, and though it may 
represent a unique CD phenotype, its underlying molecular mechanisms are unknown[22, 
23, 24]. Pediatric patients with colon-like disease were more likely to have macroscopic 
inflammation, deep ulcers, and involvement of both the ileum and colon. These data 
emphasize the need to continue and expand these studies over time to incorporate the 
evolving clinical phenotype in both adult and pediatric patients, and the need to study both 
tissues in the same patient. Only through such studies will we uncover whether the tissue of 
origin dictates potential clinical phenotype similarly.
The ileum-like CD subclass was primarily characterized by an upregulation of pathways 
involved in lipid and xenobiotic metabolism. The mechanistic link between these clinical 
phenotypes and the lipid metabolic signature defined here is yet to be explored, however the 
implication that lipid metabolism may be involved is interesting for several reasons. First, 
lipid metabolism and altered levels of certain lipids have been previously associated with 
IBD (reviewed in [25]), and may be linked to inflammation state and immune signaling 
(reviewed in [26]), in addition to diet and intestinal microbiota composition[27]. Lipid levels 
may also be a cause or result of increases in intestinal oxidative stress, which has also been 
shown to be elevated in CD patients (reviewed in [28]). Notably, two of the top differentially 
expressed genes between CD subclasses were in fact GSTA1 and GSTA2, key mediators of 
the oxidative stress response[29]. Furthermore, diet, cholesterol, and microbiota composition 
have each been studied either themselves as potential therapies or how their levels change as 
a result of surgery or biologic use (reviewed in [25]).
The diversity in cellular state demonstrated at both the transcriptional and chromatin levels 
has important potential therapeutic implications. Our results suggest that additional testing 
of CD patients for particular molecular signatures, especially metabolic pathways, may 
determine potential therapeutic subgroups. This approach has already increased our 
understanding of human cancer biology. Patient sub-classification in various forms of 
cancer, most notably invasive breast tumors[4, 5], has led to numerous associations with 
clinical outcome and helped to shape future treatment strategies. There is growing consensus 
that subtypes exist in CD as well, each with its own presentation, genetic makeup, and 
prognosis. As a first step, molecular stratifications of archived patient tissue and serum from 
major clinical trials could be performed in the context of response to biologic and microbial 
therapies for CD[30].
Our current studies did not allow for the investigation of both intestinal regions from the 
same individual, but they provide significant motivation for future exploration of these 
molecular subclasses longitudinally in larger cohorts of matched colon and ileum tissue of 
the same patient. New larger studies should allow for a more complete understanding of the 
molecular effects of host-environment interactions on disease, and its utility in guiding 
clinical decisions. In addition, our sample numbers here are too limited to study the effects 
of genetic variation on identified changes in chromatin accessibility and gene expression. 
Our chromatin accessibility data strongly suggested that changes occurred at genomic loci 
previously associated with disease through genetic variation. Future studies with larger 
Weiser et al. Page 7
Gut. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sample sizes will help identify specific relationships between genetic disease predisposition, 
regulatory activity, gene expression levels and clinical phenotypes and to better characterize 
individual-level disease sub-phenotypes within this very heterogeneous disease and tissue. 
Genomic studies on composite cell types (e.g. immune and epithelial cells) may also become 
necessary to study cell specific mechanisms driving phenotype specific disease 
pathogenesis.
MATERIALS AND METHODS
For more detailed information, see the Supplemental Methods. All processed sequencing 
data are available in GEO under accession GSE85499 with raw sequence data available 
through dbGaP. Full data tables are also hosted at http://fureylab.web.unc.edu/datasets/
crohns-disease-molecular-subtypes/.
Statistics
Differential gene expression was detected using DEseq with an adjusted p-value threshold of 
0.05. Differential chromatin accessibility was detected using a 2-sided t-test with p-value 
threshold of 0.05. Pathway enrichments were determined using GSAA (FDR<0.1, 
permutation test) for all pairwise comparisons between all CD, colon-like CD, ileum-like 
CD, and non-IBD samples based on differential gene expression p-values calculated using 2-
sided t-tests. Clinical phenotype associations were tested with 2-sided t-tests or Fisher’s 
Exact Tests.
Study Approval
All procedures were approved under University of North Carolina IRB protocols 10-0355, 
14-2445 and 11-0359.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SUMMARY BOX
What is already known about this subject
• Crohn’s disease is a clinically heterogeneous disease with variable 
presentation and progression.
• Current therapies for Crohn’s disease patients are largely based on subjective 
clinical classifications resulting in an inconsistent response. Unlike other 
complex diseases, notably certain cancers, there is currently no way to 
determine a personalized approach to therapy.
• Genetic association studies suggest that underlying molecular or genetic 
factors contribute to disease heterogeneity, but precise mechanisms are poorly 
understood.
What are the new findings
• Gene expression and chromatin accessibility can subdivide Crohn’s disease 
into at least two distinct molecular subclasses that associate with specific 
disease phenotypes.
• These subclasses exhibit stark expression differences in cellular metabolism 
and immune pathways.
• Similar molecular phenotypes are also observed in treatment-naïve pediatric 
Crohn’s disease patients, thus defining true disease subclasses independent of 
treatment history and patient age.
How might it impact on clinical practice in the foreseeable future
• Our findings thus provide evidence of a molecular basis for the observed 
heterogeneity in Crohn’s disease. They also offer a unique opportunity to 
begin exploring customized treatment options guided by disease subclass 
providing novel therapeutic avenues and predictors of disease outcomes.
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Figure 1. Two distinct molecular subtypes in adult CD
(A) PCA analysis of RNA-seq data from colon tissue from 21 CD and 11 non-IBD patients 
shows two distinct clusters. (B) 849 genes are differentially expressed between the two CD 
subclasses (adjusted p<0.05, DEseq), defined as colon-like and ileum-like. Known markers 
of colon and ileum are highlighted. (C) Genes upregulated in colon-like (top) and ileum-like 
(bottom) CD subclasses overlap previously defined colon-specific and ileum-specific genes, 
respectively. (D) Differentially accessible regions (DARs) identified using FAIRE-seq 
(p<0.05, two-sided t-test, normalized read counts, 300-bp windows) show distinct profiles in 
colon-like and ileum-like CD samples. (E) Colon-like-associated DARs are enriched and 
ileum-like-associated DARs are depleted near genes upregulated in colon-like samples 
(p≤0.01, permutation test). (F) Ileum-like-associated DARs are enriched and colon-like-
associated DARs are depleted near genes upregulated in ileum-like samples (p<0.001, 
permutation test).
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Figure 2. Treatment-naïve pediatric CD samples show similar molecular subtypes
(A) PCA analysis of combined RNA-seq data from adult colon tissue and pediatric ileum 
tissue from CD and non-IBD patients shows separation of tissue types (PC1) and replicates 
ileum-like and colon-like clusters (PC2). Expression of APOA1 (blue-pink, low-high) in 
pediatric samples aligns well with subclasses. (B) Hierarchical clustering of RNA-seq data 
using 500 colon- and ileum-specific genes show clusters of genes associated with ileum-like 
and colon-like samples across both the adult colon and pediatric ileum cohorts, as well as 
genes associated with tissue of origin.
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Figure 3. Pathways enriched for differentially expressed genes associated with CD phenotypes
Pathway enrichments were determined using GSAA (FDR<0.1, permutation test) for all 
pairwise comparisons between all CD, colon-like CD, ileum-like CD, and non-IBD samples. 
Separate analyses in (A) adult colon and (B) pediatric ileum show similar and unique 
pathways associated with CD phenotypes. Each circle represents Reactome-defined pathway 
with the size reflecting the number of genes in the pathway. Pathways were grouped based 
on similarity in gene membership, and labels describing multi-pathway clusters are shown. 
See Supplementary Figures 3–4 for CD vs non-IBD comparisons and full list of pathways.
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